MONDAY, Dec. 17, 2018 — Buprenorphine-naloxone is cost-effective compared with extended-release naltrexone for treating opioid use disorder, according to a study published online Dec. 18 in the Annals of Internal Medicine.
Sean M. Murphy, Ph.D.,… (Source: Drugs.com – Pharma News)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
